Probuphine® (buprenorphine)

Last Review Date: July 15, 2019
Number: MG.MM.PH.160

Medical Guideline Disclaimer

C All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member’s benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and website links are accurate at time of publication. EmblemHealth Services Company LLC, (“EmblemHealth”) has adopted the herein policy in providing management, administrative and other services to HIP Health Plan of New York, HIP Insurance Company of New York, Group Health Incorporated and GHI HMO Select, related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

Definition

Probuphine is indicated in patients 16 years of age and older for the maintenance treatment of opioid dependence in patients who have achieved and sustained prolonged clinical stability on low-to-moderate doses of a transmucosal buprenorphine-containing product for 3 months or longer with no need for dosing adjustments.

Length of Authorization

Coverage will be provided for 6 months and may be renewed.

Dosing Limits

Max Units (per dose and over time) [Medical Benefit]:

- 4 implants every 6 months

I. INITIAL APPROVAL CRITERIA

Probuphine may be considered medically necessary if the below conditions are met AND use is consistent with the medical necessity criteria that follows:

1. Maintenance treatment of opioid dependence in patients who meet ALL of the following criteria:
   a. Patient has clinically documented opioid dependence; AND
   b. Patient has been on low-to-moderate doses of a transmucosal buprenorphine-containing product for 3 months or longer; AND
   c. Patient has not needed dosing adjustments; AND
   d. Patient is participating in a complete treatment plan
Limitations/Exclusions

1) Approval will be granted for a maximum of 4 implants every 6 months.

II. RENEWAL CRITERIA

- Patient continues to meet INITIAL APPROVAL CRITERIA.

Dosage/Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maintenance treatment of opioid dependence</td>
<td>Insert 4 single-rod implants (each containing 74.2 mg of buprenorphine) subdermally into the inner side of the upper arm; remove after 6 months; may insert 4 new implants into other arm at time of removal</td>
</tr>
</tbody>
</table>

Applicable Procedure Codes

- J0570 Intradermal, buprenorphine, 74.2 mg, 1 billable unit = 74.2 mg

Applicable NDCs

- 58284-0100-14 Probuphine; 74.2 mg intradermal implant

Applicable Diagnosis Codes

<table>
<thead>
<tr>
<th>ICD-10</th>
<th>ICD-10 Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>F11.20</td>
<td>F11.20 Opioid dependence, uncomplicated</td>
</tr>
<tr>
<td>F11.21</td>
<td>F11.21 Opioid dependence, in remission</td>
</tr>
</tbody>
</table>

References